51 research outputs found
ΠΠ°Π»ΠΈΠ΄Π°ΡΠΈΡ ΠΈ ΠΏΠ΅ΡΠ²ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠΎΠ΄ΡΠ»Ρ EORTC QLQ PRT-23 Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π»ΡΡΠ΅Π²ΡΠΌ ΡΠ΅ΠΊΡΠΈΡΠΎΠΌ
Objective: to make the language adaptation and testing of an EORTC QLQ PRT-23 module, a method to assess quality of life, which has been elaborated in conjunction with the European organization for research and treatment of cancer quality of life questionnaire group (EORTC QLQ group), in clinical practice. Subjects and methods. An initiative study of the language adaptation of the EORTC QLQ PRT-23 module was completed. The elaborated questionnaire was tested in clinical practice. The criteria for including patients (n = 176) in the study were successful radical antitumor therapy; at least three monthsβ duration of small pelvic radiotherapy (RT); clinical Stage 0βIV according to the Radiation Therapy Oncology Group (RTOG) and EORTC; and endoscopically verified signs of developed radiation-induced rectitis (Stages 0βIV after M.S. Bardychev); no recurrence of the underlying disease throughout the follow-up; patient compliance; availability of a patient to be followed. Results. The range of performed RT in the patients included in the study protocol was as follows: 61 (34.6 %) patients had a total focal dose of RT, which was not higher than the tolerance values for the rectal mucosa (from 60 to 70 Gy); 115 (65.4 %) patients had a radiation dose range of 70 to 80 Gy. At least 3 months passed from the completion of the given RT to the study inclusion.Β With the EORTC QLQ PRT-23 module, the differences between RTOG/EORTC 0 and RTOG/EORTC IIβIV groups were as follows: p0βII < 0.02, p0βIII < 0.0001, and p0βIV < 0.0006. When the EORTC QLQ Π‘-30 and QLQ PRT-23 in RTOG/EORTC III group (n = 7) and the RTOG/EORTC 0 group, this was p0βIII < 0.002.Assessment of the QLQ Π‘-30 and QLQ PRT-23 modules and comparison of patients with RTOG/EORTC Stages I, II, and IV and those with RTOG/EORTC stage 0 revealed no statistically significant group difference: p0βI < 0.81, p0βII < 0.07, and p0βIV < 0.07, respectively.Β The use of the QLQ PRT-23 module only yielded significantly different results between the patients without chronic radiation-induced rectitis (Stage 0) and those with the endoscopic manifestations of Stages III and IV radiation-induced rectitis (p0βIII < 0.0006; p0βIV < 0.0004). The values of the EORTC QLQ Π‘-30 and QLQ PRT-23 questionnaires were statistically significantly different in the patients with endoscopically verified radiation-induced rectitis and in those without this condition (p0βI < 0.03; p0βII < 0.02; p0βIII < 0.0016; p0βIV < 0.00009).Β Conclusion. The EORTC QLQ Π‘-30 and QLQ PRT-23 questionnaires may be used in the patients with chronic radiation-induced rectitis for assessment of the quality-of-life index, for determination of the integral values over time (before, during, and after treatment), for informed involvement of a patient during treatment, for estimation of patient satisfaction with the therapy performed. The EORTC QLQ Π‘-30 questionnaire supplemented by the QLQ PRT-23 module is a subjective method. Our study provided support for the fact that the QLQ Π‘-30 and QLQ PRT-23 questionnaires for staging chronic radiation-induced rectitis must be used in combination with any third questionnaire.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΠ·ΡΠΊΠΎΠ²ΡΡ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΡ ΠΈ Π°ΠΏΡΠΎΠ±Π°ΡΠΈΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ ΠΌΠΎΠ΄ΡΠ»Ρ EORTC QLQ PRT-23 β ΠΌΠ΅ΡΠΎΠ΄Π° ΠΎΡΠ΅Π½ΠΊΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ Π½Π°ΠΌΠΈ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎ Ρ ΠΡΡΠΏΠΏΠΎΠΈΜ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ ΠΠ²ΡΠΎΠΏΠ΅ΠΈΜΡΠΊΠΎΠΈΜ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° (European organization for research and treatment of cancer quality of life questionnaire group, EORTC QLQ group). ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ ΠΈΠ½ΠΈΡΠΈΠ°ΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎ ΡΠ·ΡΠΊΠΎΠ²ΠΎΠΈΜ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ ΠΌΠΎΠ΄ΡΠ»Ρ EORTC QLQ PRT-23. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΈΜ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊ Π°ΠΏΡΠΎΠ±ΠΈΡΠΎΠ²Π°Π½ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. ΠΡΠΈΡΠ΅ΡΠΈΡΠΌΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (n = 176) Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΡΠ»ΡΠΆΠΈΠ»ΠΈ: ΡΡΠΏΠ΅ΡΠ½ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½Π°Ρ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½Π°Ρ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΡΠΎΠΊ Π΄Π°Π²Π½ΠΎΡΡΠΈ Π»ΡΡΠ΅Π²ΠΎΠΈΜ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (ΠΠ’) Π½Π° ΠΎΡΠ³Π°Π½Ρ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΡΠ°Π·Π° Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 3 ΠΌΠ΅Ρ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ (0βIV ΡΡΠ°Π΄ΠΈΠΈ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ RTOG/EORTC (Radiation therapy oncology group β Π Π°Π΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π³ΡΡΠΏΠΏΠ°)) ΠΈ ΡΠ½Π΄ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½ΡΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΡΠ°Π·Π²ΠΈΠ²ΡΠ΅Π³ΠΎΡΡ Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠ΅ΠΊΡΠΈΡΠ° (0βIV ΡΡΠ°Π΄ΠΈΠΈ ΠΏΠΎ Π.Π‘. ΠΠ°ΡΠ΄ΡΡΠ΅Π²Ρ), ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π·Π° Π²ΡΠ΅ Π²ΡΠ΅ΠΌΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ, ΠΈΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΌ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΎΠΊΠΎΠ»Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΡ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ Π΄Π»Ρ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΈΠ°ΠΏΠ°Π·ΠΎΠ½ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΈΜ ΠΠ’ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
, Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² ΠΏΡΠΎΡΠΎΠΊΠΎΠ» ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: 61 (34,6 %) ΠΏΠ°ΡΠΈΠ΅Π½Ρ β ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ ΠΎΡΠ°Π³ΠΎΠ²Π°Ρ Π΄ΠΎΠ·Π° ΠΠ’ Π½Π΅ Π²ΡΡΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΈΜ Π΄Π»Ρ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΈΜ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΏΡΡΠΌΠΎΠΈΜ ΠΊΠΈΡΠΊΠΈ (ΠΎΡ 60 Π΄ΠΎ 70 ΠΡ); Ρ 115 (65,4 %) Π±ΠΎΠ»ΡΠ½ΡΡ
Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½ Π»ΡΡΠ΅Π²ΠΎΠΈΜ Π½Π°Π³ΡΡΠ·ΠΊΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ» ΠΎΡ 70 Π΄ΠΎ 80 ΠΡ. ΠΡ ΠΌΠΎΠΌΠ΅Π½ΡΠ° Π·Π°Π²Π΅ΡΡΠ΅Π½ΠΈΡ ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΎ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π² Π½Π°ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ»ΠΎ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 3 ΠΌΠ΅Ρ.Β ΠΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠΎΠ΄ΡΠ»Ρ QLQ PRT-23 ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ RTOG/EORTC 0 ΠΈ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ RTOG/EORTC IIβIV: p0βII < 0,02; p0βIII < 0,0001; p0βIV < 0,0006. ΠΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠΎΠ² EORTC QLQ Π‘-30 ΠΈ QLQ PRT-23 Π² Π³ΡΡΠΏΠΏΠ΅ RTOG/EORTC III (n = 7) ΠΈ Π² Π³ΡΡΠΏΠΏΠ΅ RTOG/EORTC 0: p0βIII < 0,002.ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎ Π±Π°Π·ΠΎΠ²ΡΠΌ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠΎΠΌ QLQ Π‘-30 ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΌ ΠΌΠΎΠ΄ΡΠ»Π΅ΠΌ QLQ PRT-23, ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎ RTOG/EORTC I, II, IV ΡΡΠ°Π΄ΠΈΠΈΜ Ρ RTOG/EORTC 0 ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠΈΜ ΡΠ°Π·Π½ΠΈΡΡ: p0βI < 0,81; p0βII < 0,07; p0βIV < 0,07 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ.Β ΠΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΎΠ»ΡΠΊΠΎ ΠΌΠΎΠ΄ΡΠ»Ρ QLQ PRT-23 ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠΎΠΈΜ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠ΅ΠΊΡΠΈΡΠ° (ΡΡΠ°Π΄ΠΈΡ 0) ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ ΡΠ½Π΄ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠ΅ΠΊΡΠΈΡΠ° III ΠΈ IV ΡΡΠ°Π΄ΠΈΠΈΜ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ (p0βIII < 0,0006; p0βIV < 0,0004). ΠΠ½Π°ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΠΎΠ² EORTC QLQ Π‘-30 ΠΈ QLQ PRT-23 ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΎΡΠ»ΠΈΡΠ°Π»ΠΈΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠ½Π΄ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½ΡΠΌ Π»ΡΡΠ΅Π²ΡΠΌ ΡΠ΅ΠΊΡΠΈΡΠΎΠΌ ΠΎΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±Π΅Π· Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠ΅ΠΊΡΠΈΡΠ° (p0βI < 0,03; p0βII < 0,02; p0βIII < 0,0016; p0βIV < 0,00009).Β ΠΡΠ²ΠΎΠ΄Ρ. ΠΠΏΡΠΎΡΠ½ΠΈΠΊ EORTC QLQ Π‘-30, Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΡΠΈΜ ΠΌΠΎΠ΄ΡΠ»Π΅ΠΌ QLQ PRT-23, ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΡΡΠ΅Π²ΡΠΌ ΡΠ΅ΠΊΡΠΈΡΠΎΠΌ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΈΠ½ΡΠ΅Π³ΡΠ°Π»ΡΠ½ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΈΜ Π² Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ (Π΄ΠΎ, Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΈ ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ), Π΄Π»Ρ ΠΈΠ½ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ Π² ΠΏΡΠΎΡΠ΅ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΎΡΠ΅Π½ΠΊΠΈ Π΅Π³ΠΎ ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠ΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΈΜ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΈΜ. ΠΠΎ ΡΡΠΎΡ ΠΌΠ΅ΡΠΎΠ΄ ΠΎΡΠ΅Π½ΠΊΠΈ Π½Π΅Π»ΡΠ·Ρ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ Π΄Π»Ρ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΡΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠ΅ΠΊΡΠΈΡΠ°.
Π’ΡΡΠ΄Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ ΠΏΠΎΡΠ»Π΅ COVID-19. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ»ΡΡΠ°ΠΉ
The severe course of the new coronavirus infection (COVID-19) is associated with multiple life-threatening complications that lead to delayed initiation of active rehabilitation and unfavorable long-term treatment outcomes. Tracheoesophageal fistula is one of these complications. The specific feature of this event in COVID-19 is delayed tissue regeneration which requires a non-standard approach to management of such patients.The article presents a clinical case of a pregnant patient after a complicated severe course of COVID-19 with the development of tracheoesophageal fistula, sepsis, and weakness syndrome acquired in ICU. The combination of complications of the disease led to a prolonged (about five months) period of rehabilitation.Modern standard components of intensive therapy of such patients including regular monitoring of endotracheal/tracheostomy tube cuff pressure, dynamic assessment of nutritional status and its correction, rational antimicrobial therapy, screening of psychiatric disorders and early rehabilitation, will minimize the number of both early and delayed complications of COVID-19. Β Π’ΡΠΆΠ΅Π»ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (COVID-19) ΡΠΎΠΏΡΡΠΆΠ΅Π½ΠΎ ΡΠΎ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²ΠΎΠΌ ΠΆΠΈΠ·Π½Π΅ΡΠ³ΡΠΎΠΆΠ°ΡΡΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡ ΠΊ ΠΎΡΡΡΠΎΡΠΊΠ΅ Π½Π°ΡΠ°Π»Π° Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΈ ΡΡ
ΡΠ΄ΡΠ΅Π½ΠΈΡ Π΄ΠΎΠ»Π³ΠΎΡΡΠΎΡΠ½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· ΡΠ°ΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Ρ
Π΅ΠΎΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ²ΠΈΡΠ°. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ ΡΡΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡΠΈ COVID-19 ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π°ΠΌΠ΅Π΄Π»Π΅Π½Π½Π°Ρ ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΡ ΡΠΊΠ°Π½Π΅ΠΉ, ΡΡΠΎ ΡΡΠ΅Π±ΡΠ΅Ρ Π½Π΅ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ ΡΠ°ΠΊΡΠΈΠΊΠ΅ Π²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ°ΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ»ΡΡΠ°ΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ COVID-19 Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ ΡΡΠ°Ρ
Π΅ΠΎΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ²ΠΈΡΠ°, ΡΠ΅ΠΏΡΠΈΡΠ°, ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½Π½ΠΎΠΉ Π² ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ ΡΠ΅Π°Π½ΠΈΠΌΠ°ΡΠΈΠΈ ΠΈ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ»Π°Π±ΠΎΡΡΠΈ. ΠΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΡΠΈΠ²Π΅Π»Π° ΠΊ Π·Π°ΡΡΠΆΠ½ΠΎΠΌΡ (ΠΎΠΊΠΎΠ»ΠΎ 5 ΠΌΠ΅Ρ.) ΠΏΠ΅ΡΠΈΠΎΠ΄Ρ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ.Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ°ΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²ΠΊΠ»ΡΡΠ°Ρ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΡΠΉ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π΄Π°Π²Π»Π΅Π½ΠΈΡ Π² ΠΌΠ°Π½ΠΆΠ΅ΡΠ΅ ΡΠ½Π΄ΠΎΡΡΠ°Ρ
Π΅Π°Π»ΡΠ½ΡΡ
/ΡΡΠ°Ρ
Π΅ΠΎΡΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΡΠ±ΠΎΠΊ, Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΡΡ ΠΎΡΠ΅Π½ΠΊΡ Π½ΡΡΡΠΈΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° ΠΈ Π΅Π³ΠΎ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ, ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ Π°Π½ΡΠΈΠΌΠΈΠΊΡΠΎΠ±Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΠΈ ΡΠ°Π½Π½ΡΡ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡ ΠΌΠΈΠ½ΠΈΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΡΠΈΡΠ»ΠΎ ΠΊΠ°ΠΊ ΡΠ°Π½Π½ΠΈΡ
, ΡΠ°ΠΊ ΠΈ ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ COVID-19
PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
Abstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into the study. Melatonin (Melaxen, Unifarm, USA) was administered as a single daily dose of 0.003 g, at 21.00, accompanied by a standard therapy in twenty BA patients for 21 days. We determined contents and functional properties of Π’- and B-lymphocytes, mononuclear phagocytes, IgE, IL-4, IFNΞ³ levels, as well as melatonin concentrations in blood serum in the morning and evening time. When included into BA treatment protocol, melatonin proved to cause partial restoration of circadian rhythm for Tand B cell subpopulations, mononuclear phagocytes, cytokine production, due to its chronotropic and immunomodulating activity. This effect is associated with a more pronounced clinical effect, thus presuming reversibility of desynchronosis state
Analysis of the Incidence of the Female Population Omsk Region with Breast Cancer for Ten Years of (2003 - 2012)
The paper presents the epidemiological characteristics of diseases of the female population of the Omsk region of breast cancer (BC) from 2003 to 2012, Determined the dynamics of morbidity. A comparative analysis of breast cancer incidence rates in urban and rural residents of the area. In the structure of malignant tumors of the female population of the Omsk region the proportion of breast cancer was 23.3% and was lower than the national average (20.0%). In rural areas, compared with the regional center had higher growth rates of incidence of breast cancer (1.5-fold)
Method of Prediction the Performance of Electrochemical Batteries, Long Working in Power Plant of Space-rocket Objects
Abstract Causes of degradation of electrochemical batteries, constituent in the power-supply system of objects of space-rocket technology, in the article are studied. Methods of determin ing the battery life time reduced. With no possibility of an experiment or a lack of time, the method of battery life time predict ion is proposed for use. This method is based on the mathematical model, wh ich is based on experimental data obtained in the battery life tests. The equations included in this mathematical model are presented. Reco mmendations for the use of method of prediction are p resente
Validation and the first results of clinical use of an EORTC QLQ PRT-23 module to assess quality of life in patients with radiation-induced rectitis
Objective: to make the language adaptation and testing of an EORTC QLQ PRT-23 module, a method to assess quality of life, which has been elaborated in conjunction with the European organization for research and treatment of cancer quality of life questionnaire group (EORTC QLQ group), in clinical practice. Subjects and methods. An initiative study of the language adaptation of the EORTC QLQ PRT-23 module was completed. The elaborated questionnaire was tested in clinical practice. The criteria for including patients (n = 176) in the study were successful radical antitumor therapy; at least three monthsβ duration of small pelvic radiotherapy (RT); clinical Stage 0βIV according to the Radiation Therapy Oncology Group (RTOG) and EORTC; and endoscopically verified signs of developed radiation-induced rectitis (Stages 0βIV after M.S. Bardychev); no recurrence of the underlying disease throughout the follow-up; patient compliance; availability of a patient to be followed. Results. The range of performed RT in the patients included in the study protocol was as follows: 61 (34.6 %) patients had a total focal dose of RT, which was not higher than the tolerance values for the rectal mucosa (from 60 to 70 Gy); 115 (65.4 %) patients had a radiation dose range of 70 to 80 Gy. At least 3 months passed from the completion of the given RT to the study inclusion.Β With the EORTC QLQ PRT-23 module, the differences between RTOG/EORTC 0 and RTOG/EORTC IIβIV groups were as follows: p0βII < 0.02, p0βIII < 0.0001, and p0βIV < 0.0006. When the EORTC QLQ Π‘-30 and QLQ PRT-23 in RTOG/EORTC III group (n = 7) and the RTOG/EORTC 0 group, this was p0βIII < 0.002.Assessment of the QLQ Π‘-30 and QLQ PRT-23 modules and comparison of patients with RTOG/EORTC Stages I, II, and IV and those with RTOG/EORTC stage 0 revealed no statistically significant group difference: p0βI < 0.81, p0βII < 0.07, and p0βIV < 0.07, respectively.Β The use of the QLQ PRT-23 module only yielded significantly different results between the patients without chronic radiation-induced rectitis (Stage 0) and those with the endoscopic manifestations of Stages III and IV radiation-induced rectitis (p0βIII < 0.0006; p0βIV < 0.0004). The values of the EORTC QLQ Π‘-30 and QLQ PRT-23 questionnaires were statistically significantly different in the patients with endoscopically verified radiation-induced rectitis and in those without this condition (p0βI < 0.03; p0βII < 0.02; p0βIII < 0.0016; p0βIV < 0.00009).Β Conclusion. The EORTC QLQ Π‘-30 and QLQ PRT-23 questionnaires may be used in the patients with chronic radiation-induced rectitis for assessment of the quality-of-life index, for determination of the integral values over time (before, during, and after treatment), for informed involvement of a patient during treatment, for estimation of patient satisfaction with the therapy performed. The EORTC QLQ Π‘-30 questionnaire supplemented by the QLQ PRT-23 module is a subjective method. Our study provided support for the fact that the QLQ Π‘-30 and QLQ PRT-23 questionnaires for staging chronic radiation-induced rectitis must be used in combination with any third questionnaire
The Long-Term Dynamics of the Incidence of Prostate Cancer in the Omsk Region
The purpose of this study is to assess the dynamics of the incidence of prostate cancer in the Omsk region for the period 2006β 2017. Materials and methods. A retrospective epidemiological analysis of data from statistical reports (Form No. 7) of the Omsk Oblast health authorities for the period 2006β2017 was carried out. Results and its discussion. In the structure of oncological morbidity in the male population of the Omsk Region, the proportion of prostate cancer was 16.3% and was lower than the average Russian average (17%). In rural areas, compared with the regional center, higher rates of increase in the incidence of prostate cancer were observed (by 1.2 times). In general, the situation on the territory of the Omsk Region is similar to the global trend, characterized by an increase in the incidence of the male population of prostate cancer, which is a reflection of insufficient attention to primary cancer prevention, features of the socio-economic situation in the Russian Federation.Β Findings. 1. In the long-term dynamics of incidence of prostate cancer in the region for the period 2006β2017. there was a moderately pronounced upward trend in indicators (Tpr. = 3.94%; p < 0.05), with higher growth rates (1.2 times) in rural areas compared to the regional center (respectively, 3.56% and 3.04%; p < 0.001). 2. From 2006 to 2017 incidence of prostate cancer in the Omsk region increased 2.3 times in total (from 29.2 to 66.2 per 100 ths) and 1.8 times in standardized indicators (from 24.8 to 44.4 per 100 ths). 3. Despite the obvious relevance of the pathology, the prevalence of known risk factors for the development of prostate cancer in the Omsk Region has not been studied sufficiently, which requires scientific justification and improvement of approaches to primary prevention with regard to regional characteristics
- β¦